{"id":477018,"date":"2020-03-31T17:10:01","date_gmt":"2020-03-31T17:10:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=477018"},"modified":"2020-03-31T17:10:01","modified_gmt":"2020-03-31T17:10:01","slug":"small-cell-lung-cancer-clinical-trial-insight-pipeline-assessment-emerging-drugs-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/small-cell-lung-cancer-clinical-trial-insight-pipeline-assessment-emerging-drugs-delveinsight_477018.html","title":{"rendered":"Small Cell Lung Cancer Clinical Trial Insight, Pipeline Assessment, Emerging Drugs | DelveInsight"},"content":{"rendered":"
\"Small<\/a><\/p>\n
\n
Small Cell Lung Cancer Pipeline Insight, 2020<\/div>\n<\/div>\n<\/div>\n

 <\/p>\n

“Small Cell Lung Cancer Pipeline Insight, 2020<\/a>” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Small Cell Lung Cancer <\/strong>market. A detailed picture of the Small Cell Lung Cancer <\/strong>pipeline landscape is provided, which includes the disease overview and Small Cell Lung Cancer <\/strong>treatment guidelines. The assessment part of the report embraces in-depth Small Cell Lung Cancer <\/strong>commercial assessment and clinical assessment of the Small Cell Lung Cancer <\/strong>pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Small Cell Lung Cancer <\/strong>collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.<\/p>\n

Drugs covered in the report<\/strong><\/p>\n

    \n
  1. Imfinzi +\/- tremelimumab<\/li>\n
  2. Lurbinectedin (PM01183)<\/li>\n
  3. RRx-001<\/li>\n
  4. Dinutuximab (Unituxin)<\/li>\n
  5. Irinotecan liposome injection<\/li>\n
  6. Trilaciclib (G1T28)<\/li>\n
  7. Dendritic Cell-based p53 Vaccine + Nivolumab + Ipilimumab<\/li>\n
  8. Guadecitabine + Carboplatin<\/li>\n
  9. Iclusig (ponatinib)<\/li>\n<\/ol>\n

    And many others<\/p>\n

    The SCLC Market Key Players are:-<\/strong><\/p>\n

      \n
    1. AstraZeneca<\/li>\n
    2. EpicentRx<\/li>\n
    3. United Therapeutics<\/li>\n
    4. Ipsen<\/li>\n
    5. G1 Therapeutics<\/li>\n
    6. MultiVir<\/li>\n
    7. Otsuka Holdings<\/li>\n
    8. Takeda<\/li>\n<\/ol>\n

       <\/strong><\/p>\n

      Request for Free Sample: @<\/strong> https:\/\/www.delveinsight.com\/sample-request\/small-cell-lung-cancer-pipeline-insight<\/a><\/p>\n

       <\/strong><\/p>\n

      \"\"<\/strong><\/p>\n

      Small Cell Lung Cancer Analytical Perspective by DelveInsight<\/strong><\/p>\n